The beneficial effects of glycoprotein IIb/IIIa receptor antagonists in preventing ischemic complications during percutaneous coronary intervention have been established in a series of controlled ...

The Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial showed that the direct thrombin inhibitor bivalirudin, with provisional glycoprotein (Gp) IIb/IIIa ...

The currently available antiplatelet drugs target key steps of platelet activation including thromboxane A 2 synthesis, ADP-mediated signaling, and glycoprotein IIb/IIIa-mediated platelet aggregation.